137 related articles for article (PubMed ID: 28209621)
1. Prominent Oncogenic Roles of EVI1 in Breast Carcinoma.
Wang H; Schaefer T; Konantz M; Braun M; Varga Z; Paczulla AM; Reich S; Jacob F; Perner S; Moch H; Fehm TN; Kanz L; Schulze-Osthoff K; Lengerke C
Cancer Res; 2017 Apr; 77(8):2148-2160. PubMed ID: 28209621
[TBL] [Abstract][Full Text] [Related]
2. EVI1 promotes tumor growth via transcriptional repression of MS4A3.
Heller G; Rommer A; Steinleitner K; Etzler J; Hackl H; Heffeter P; Tomasich E; Filipits M; Steinmetz B; Topakian T; Klingenbrunner S; Ziegler B; Spittler A; Zöchbauer-Müller S; Berger W; Wieser R
J Hematol Oncol; 2015 Mar; 8():28. PubMed ID: 25886616
[TBL] [Abstract][Full Text] [Related]
3. Ecotropic viral integration site 1, a novel oncogene in prostate cancer.
Queisser A; Hagedorn S; Wang H; Schaefer T; Konantz M; Alavi S; Deng M; Vogel W; von Mässenhausen A; Kristiansen G; Duensing S; Kirfel J; Lengerke C; Perner S
Oncogene; 2017 Mar; 36(11):1573-1584. PubMed ID: 27617580
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer.
Jazaeri AA; Ferriss JS; Bryant JL; Dalton MS; Dutta A
Gynecol Oncol; 2010 Aug; 118(2):189-95. PubMed ID: 20462630
[TBL] [Abstract][Full Text] [Related]
5. Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.
Sayadi A; Jeyakani J; Seet SH; Wei CL; Bourque G; Bard FA; Jenkins NA; Copeland NG; Bard-Chapeau EA
Oncogene; 2016 May; 35(18):2311-21. PubMed ID: 26234679
[TBL] [Abstract][Full Text] [Related]
6. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
[TBL] [Abstract][Full Text] [Related]
7. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
Nanjundan M; Nakayama Y; Cheng KW; Lahad J; Liu J; Lu K; Kuo WL; Smith-McCune K; Fishman D; Gray JW; Mills GB
Cancer Res; 2007 Apr; 67(7):3074-84. PubMed ID: 17409414
[TBL] [Abstract][Full Text] [Related]
8. EVI1, a target gene for amplification at 3q26, antagonizes transforming growth factor-β-mediated growth inhibition in hepatocellular carcinoma.
Yasui K; Konishi C; Gen Y; Endo M; Dohi O; Tomie A; Kitaichi T; Yamada N; Iwai N; Nishikawa T; Yamaguchi K; Moriguchi M; Sumida Y; Mitsuyoshi H; Tanaka S; Arii S; Itoh Y
Cancer Sci; 2015 Jul; 106(7):929-37. PubMed ID: 25959919
[TBL] [Abstract][Full Text] [Related]
9. The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells.
Maicas M; Vázquez I; Alis R; Marcotegui N; Urquiza L; Cortés-Lavaud X; Cristóbal I; García-Sánchez MA; Odero MD
Biochim Biophys Acta Gene Regul Mech; 2017 Jun; 1860(6):721-729. PubMed ID: 28391050
[TBL] [Abstract][Full Text] [Related]
10. EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells.
Rommer A; Steinmetz B; Herbst F; Hackl H; Heffeter P; Heilos D; Filipits M; Steinleitner K; Hemmati S; Herbacek I; Schwarzinger I; Hartl K; Rondou P; Glimm H; Karakaya K; Krämer A; Berger W; Wieser R
PLoS One; 2013; 8(2):e56308. PubMed ID: 23457546
[TBL] [Abstract][Full Text] [Related]
11. Expression and activation of P38 MAP kinase in invasive ductal breast cancers: correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins.
Merlin JL; Harlé A; Lion M; Ramacci C; Leroux A
Oncol Rep; 2013 Oct; 30(4):1943-8. PubMed ID: 23900300
[TBL] [Abstract][Full Text] [Related]
12. EVI‑1 acts as an oncogene and positively regulates calreticulin in breast cancer.
Wu L; Wang T; He D; Li X; Jiang Y
Mol Med Rep; 2019 Mar; 19(3):1645-1653. PubMed ID: 30592274
[TBL] [Abstract][Full Text] [Related]
13. HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1.
Yang Y; Leonard M; Zhang Y; Zhao D; Mahmoud C; Khan S; Wang J; Lower EE; Zhang X
Cancer Res; 2018 Jan; 78(2):422-435. PubMed ID: 29187405
[TBL] [Abstract][Full Text] [Related]
14. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.
Mateo F; Arenas EJ; Aguilar H; Serra-Musach J; de Garibay GR; Boni J; Maicas M; Du S; Iorio F; Herranz-Ors C; Islam A; Prado X; Llorente A; Petit A; Vidal A; Català I; Soler T; Venturas G; Rojo-Sebastian A; Serra H; Cuadras D; Blanco I; Lozano J; Canals F; Sieuwerts AM; de Weerd V; Look MP; Puertas S; García N; Perkins AS; Bonifaci N; Skowron M; Gómez-Baldó L; Hernández V; Martínez-Aranda A; Martínez-Iniesta M; Serrat X; Cerón J; Brunet J; Barretina MP; Gil M; Falo C; Fernández A; Morilla I; Pernas S; Plà MJ; Andreu X; Seguí MA; Ballester R; Castellà E; Nellist M; Morales S; Valls J; Velasco A; Matias-Guiu X; Figueras A; Sánchez-Mut JV; Sánchez-Céspedes M; Cordero A; Gómez-Miragaya J; Palomero L; Gómez A; Gajewski TF; Cohen EEW; Jesiotr M; Bodnar L; Quintela-Fandino M; López-Bigas N; Valdés-Mas R; Puente XS; Viñals F; Casanovas O; Graupera M; Hernández-Losa J; Ramón Y Cajal S; García-Alonso L; Saez-Rodriguez J; Esteller M; Sierra A; Martín-Martín N; Matheu A; Carracedo A; González-Suárez E; Nanjundan M; Cortés J; Lázaro C; Odero MD; Martens JWM; Moreno-Bueno G; Barcellos-Hoff MH; Villanueva A; Gomis RR; Pujana MA
Oncogene; 2017 May; 36(19):2737-2749. PubMed ID: 27991928
[TBL] [Abstract][Full Text] [Related]
15. The role of EVI1 in myeloid malignancies.
Glass C; Wilson M; Gonzalez R; Zhang Y; Perkins AS
Blood Cells Mol Dis; 2014; 53(1-2):67-76. PubMed ID: 24495476
[TBL] [Abstract][Full Text] [Related]
16. Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes.
Konrad TA; Karger A; Hackl H; Schwarzinger I; Herbacek I; Wieser R
J Leukoc Biol; 2009 Oct; 86(4):813-22. PubMed ID: 19605700
[TBL] [Abstract][Full Text] [Related]
17. EVI1 splice variants modulate functional responses in ovarian cancer cells.
Dutta P; Bui T; Bauckman KA; Keyomarsi K; Mills GB; Nanjundan M
Mol Oncol; 2013 Jun; 7(3):647-68. PubMed ID: 23517670
[TBL] [Abstract][Full Text] [Related]
18. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions.
Wieser R
Gene; 2007 Jul; 396(2):346-57. PubMed ID: 17507183
[TBL] [Abstract][Full Text] [Related]
19. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
Fenouille N; Bassil CF; Ben-Sahra I; Benajiba L; Alexe G; Ramos A; Pikman Y; Conway AS; Burgess MR; Li Q; Luciano F; Auberger P; Galinsky I; DeAngelo DJ; Stone RM; Zhang Y; Perkins AS; Shannon K; Hemann MT; Puissant A; Stegmaier K
Nat Med; 2017 Mar; 23(3):301-313. PubMed ID: 28191887
[TBL] [Abstract][Full Text] [Related]
20. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.
Vasyutina E; Boucas JM; Bloehdorn J; Aszyk C; Crispatzu G; Stiefelhagen M; Breuer A; Mayer P; Lengerke C; Döhner H; Beutner D; Rosenwald A; Stilgenbauer S; Hallek M; Benner A; Herling M
Leukemia; 2015 Oct; 29(10):2003-14. PubMed ID: 25936528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
